VWVictoria Wittner

Victoria Wittner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victoria Wittner has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining Core Functions and Forms for the Implementation of Pharmacogenomics Testing in Primary Care

    by Sanjana Ramesh, Larisa H. Cavallari, Victoria Wittner, Josiah Allen, Mari Angelica S. Cayabyab, Emily J. Cicali, Nihal El Rouby, Shayna R. Killam, Nita Limdi, Mohamed Nagy, et al.

    Pharmacogenomics (PGx), utilizing a patient's DNA to individualize medication prescribing, minimizes adverse events and improves patient outcomes. However, the integration of PGx into primary care remains sparse. PGx testing encompasses multiple components and can be considered a complex health intervention. We conducted an in‐person workshop with early adopters from the Pharmacogenomics Global Research Network Implementation Working Group, followed by qualitative interviews with key opinion leaders, to identify the core functions and forms necessary for implementing PGx testing in primary care. Workshop participants agreed on six core functions necessary to implement PGx‐guided medication prescribing in primary care settings: patient identification, test ordering, laboratory testing, returning results, providing medication recommendations, and modifying pharmacotherapy. An additional function, leadership engagement, was proposed by key opinion leaders. There was considerable variation in the forms, depending on local context and available resources. In this position paper, we discuss why it is critical to separately define the core functions required to implement PGx testing in primary care settings and the customizable forms used for local execution. Defining core functions provides an actionable first step to guide scalable and context‐sensitive integration of PGx testing into routine primary care practice, balancing the need for both fidelity and adaptation in real‐world implementation.

  • Open Access

    Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer

    by Arravinth Anantharajah, Raza Chaudhry, Victoria A. Wittner, Mari Angelica S. Cayabyab, Glenda Hoffecker, Xingmei Wang, Laura J. Conway, Ursina R. Teitelbaum, Sony Tuteja

    Pharmacogenetics (PGx) applies knowledge of drug‐gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT‐GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non‐White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge ( β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female ( β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self‐reported health literacy ( β = 2.2, 95% CI [0.9, 3.5], p < 0.001). Participants were less willing to undergo testing if they had health insurance concerns ( β = −3.7, 95% CI [−5.8, −1.7], p < 0.001) or did not complete secondary education ( β = −2.0, 95% CI [−3.5, −0.6], p = 0.006). Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient‐informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research‐engaged and from a single institution, the study population may not be widely generalizable.


  • Open Access

    Patient and provider perspectives on the implementation of DPYD testing in oncology care clinics in an academic health system

    by Victoria Wittner, Jasmine Purcell, Mari Cayabyab, Glenda Hoffecker, Jillian Kalman, Ursina Teitelbaum, Robert Schnoll, Katharine A. Rendle, Sony Tuteja


  • Open Access

    Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial

    by Sony Tuteja, Mari Angelica S. Cayabyab, Glenda Hoffecker, Lisa A. Varughese, Jean de Dieu Ndayishimiye, Victoria A. Wittner, Xingmei Wang, Rachel Hatch, Donna Capozzi, Margaret Harr, et al.

    PURPOSE: To determine the feasibility and effectiveness of implementing pretreatment DPYD/UGT1A1 testing in patients with gastrointestinal cancer and its impact compared with a biobank population. MATERIALS AND METHODS: A prospective, nonrandomized implementation trial of pretreatment DPYD/UGT1A1 testing with preemptive dose reduction was conducted in patients initiating treatment with a fluoropyrimidine (FP, [fluorouracil or capecitabine]) or irinotecan. The primary end point was feasibility, defined as proportion of results available prior to cycle 1 of treatment. Secondarily, occurrence of severe treatment-related adverse events (TRAEs), defined as toxicity resulting in hospitalization or emergency department visit, was compared with a biobank population receiving standard dose chemotherapy. RESULTS: Of the 288 patients prospectively tested, 225 (median age 60.7 years, 54% male, 18% Black, 47% colorectal cancer) received a qualifying chemotherapy. Eight of 11 DPYD variant carriers received an FP and eight of 39 UGT1A1 poor metabolizers received irinotecan. The median test turnaround time was 10 days (IQR, 9-13) with 57.4% of results available before cycle 1. Eleven of 16 (69%) participants with a drug-gene interaction (DGI) had results available before chemotherapy initiation and received pharmacogenetic-recommended dose reductions. Compared with the biobank cohort (n = 229), the prospective DGI group experienced fewer severe TRAEs (38% v 65%, P = .123), treatment discontinuations (31% v 47%, P = .356), and treatment modifications (38% v 76%, P = .028). CONCLUSION: Pretreatment DPYD/UGT1A1 testing and dose reduction was feasible, enabling clinicians to make the appropriate chemotherapy dose reductions, reducing occurrence of adverse outcomes. DPYD/UGT1A1 testing is an important precision oncology approach to optimize patient safety.


  • Open Access

    A call for reporting of tumor‐specific outcomes in studies of DPYD genotyping

    by Jean De Dieu Ndayishimiye, Mari Cayabyab, Glenda Hoffecker, Victoria Wittner, Penn Medicine Biobank, Sony Tuteja